RNA-seq data indicated that these drugs can promote disease alleviation through increased expression of several innate immune response-related genes previously demonstrated to impact CDI, including those involved in the recruitment of neutrophils, the production of interleukin 33 (IL-33), and the IL-22 signaling pathway [124]. Here, IL33 is linked to clostridium difficile infection.